Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,010.53 -61.10 (-1.20%) Dow
37,877.31 -583.61 (-1.52%) Nasdaq
15,452.16 -260.59 (-1.66%) Bitcoin USD
63,600.39 -1,206.47 (-1.86%) CMC Crypto 200
1,373.10 -9.48 (-0.69%)
Immunocore Holdings plc (IMCR)
| Previous close | 58.47 |
| Open | 57.34 |
| Bid | 57.79 x 100 |
| Ask | 58.17 x 100 |
| Day's range | 57.34 - 58.37 |
| 52-week range | 42.21 - 76.98 |
| Volume | |
| Avg. volume | 504,179 |
| Market cap | 2.827B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.41 |
| Earnings date | 08 May 2024 - 12 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 86.07 |
GlobeNewswireImmunocore announces upcoming presentation and posters at ASCO 2024
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 24 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to ra
- GlobeNewswire
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor confere
- GlobeNewswire
Immunocore presented two posters at CROI 2024
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 05 March 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases,
